Insiders · Profile

Rangwala Reshma

EVP & Chief Medical Officer at Karyopharm Therapeutics. Filing since 20 Apr 2023. CIK 0001825322

Company

Date

Role

Action

Shares

Amount

Of holding

KPTI Karyopharm Therapeutics Inc.

14 May 2026

EVP & Chief Medical Officer

Sold at will

408

$3.88K

0.7%

KPTI Karyopharm Therapeutics Inc.

21 Apr 2026

EVP & Chief Medical Officer

Sold at will

449

$4.01K

0.8%

KPTI Karyopharm Therapeutics Inc.

2 Mar 2026

EVP & Chief Medical Officer

Sold at will

5,066

$47.67K

8.2%

KPTI Karyopharm Therapeutics Inc.

15 Sep 2025

EVP & Chief Medical Officer

Sold at will

408

$2.62K

1.4%

KPTI Karyopharm Therapeutics Inc.

23 Apr 2025

EVP & Chief Medical Officer

Sold at will

419

$2.59K

1.4%

KPTI Karyopharm Therapeutics Inc.

4 Mar 2025

EVP & Chief Medical Officer

Sold at will

3,587

$22.56K

10.9%

KPTI Karyopharm Therapeutics Inc.

22 Apr 2024

EVP & Chief Medical Officer

Sold at will

6,789

$7.94K

1.9%

KPTI Karyopharm Therapeutics Inc.

1 Mar 2024

EVP & Chief Medical Officer

Sold at will

5,969

$7.16K

1.7%

KPTI Karyopharm Therapeutics Inc.

29 Feb 2024

EVP & Chief Medical Officer

Sold at will

15,667

$18.33K

4.2%

KPTI Karyopharm Therapeutics Inc.

20 Apr 2023

EVP & Chief Medical Officer

Sold on a plan

6,770

$27.42K

4.1%

10 decisions on file.